kdm1a/lsd1

DDP-38003 dihydrochloride is an orally available histone lysine-specific demethylase 1A (KDM1A/LSD1) inhibitor (IC50: 84 nM).

TAK-418 is a selective and orally active inhibitor of LSD1/KDM1A enzyme with an IC50 of 2.9 nM. TAK-418 unlocks abnormal epigenetic mechanisms and improves autism symptoms in models of neurodevelopmental disorders.

Pulrodemstat HCl is an orally active, selective and potent lysine demethylase-1 (LSD1) inhibitor, and a selective KDM1A inhibitor, with anticancer and anti-proliferative activities, inhibiting HNSCC cell proliferation and migration Inhibits the growth of head and neck squamous cell carcinoma by triggering apoptosis.

DDP-38003 trihydrochloride is a novel, orally available histone lysine-specific demethylase 1A (KDM1A/LSD1) inhibitor with an IC50 of 84 nM.

Seclidemstat mesylate (SP-2577) is a highly effective and reversible inhibitor of KDM1A (LSD1), with a Ki of 31 nM and an IC50 of 13 nM. It shows promising potential in enhancing antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer and exhibits inhibitory effects on virus production, viral DNA replication, and late gene expression. Additionally, seclidemstat mesylate is a valuable tool for studying Ewing Sarcoma in research settings.

Seclidemstat (SP-2577) is an effective LSD1 inhibitor, with a mean IC50 of 127 nM.

Iadademstat dihydrochloride (ORY-1001(trans)) , a Potent and Selective Covalent KDM1A/LSD1 Inhibitor, for the Treatment of Acute Leukemia.

FY-56, a highly potent and selective inhibitor of LSD1/KDM1A with an IC50 value of 42 nM, demonstrates significant selectivity over MAO-A/B. This compound effectively induces differentiation in MOLM-13 and MV4-11 cells, showing promise for acute myeloid leukemia (AML) research [1].

ORY1001 (ORY 1001) is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor, with high selectivity against related FAD dependent aminoxidases with IC50 of <20 nM.